Companies: 10,795·Total market cap: $144.5T
Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.

TRDANASDAQHealthcare● Active
$6.26
$-0.11(-1.73%)
Market Cap$243017056
P/E Ratio
52W High$16.45
52W Low$4.93
Overview

Entrada Therapeutics, Inc. (TRDA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

trda · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

SellBuy

Buy

5 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
3
Hold
2
Sell
0
Strong Sell
0
Total: 5 · Buy rate: 60.0%

12-Month Price Target

High

$21.00

Consensus

$16.00

+155.6% upside

Low

$10.00

Median: $17 · Last Close: $6.26

The Entrada Therapeutics, Inc. (TRDA) analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month TRDA price target is $16.00, representing +155.6% upside from the current price of $6.26.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $16 (155.6%)

Consensus Target

$16.00

155.6% upside

High Target

$21

235.5%

Low Target

$10

59.7%

Current Price

$6.26

as of today

Based on analyst price targets, the TRDA stock price prediction for the next 12 months ranges from $10 to $21. The consensus TRDA price forecast of $16.00 implies 155.6% upside from the current price of $6.26.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$6.230.42%

1-day model range: $6.1–$6.37. Peak: $6.37 (-0.42%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$8+27.0%
2028$9+44.1%
2029$10+53.8%
2030$10+59.0%
2031+61.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)55.4Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · TRDA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$6.57SELL
MA 10$6.70SELL
MA 20$6.60SELL
MA 50$10.54SELL
MA 100$11.07SELL
MA 200$9.41SELL
Current $TRDA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$6.52SELL
EMA 10$6.68SELL
EMA 20$7.41SELL
EMA 50$9.29SELL
EMA 100$10.05SELL
EMA 200$10.04SELL
Current $TRDA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-08
Downgrade ↓
BuyNeutral
Oppenheimer2026-04-06
Maintains
OutperformOutperform
HC Wainwright & Co.2026-02-18
Maintains
BuyBuy
HC Wainwright & Co.2025-05-20
Maintains
BuyBuy
HC Wainwright & Co.2025-03-31
Maintains
BuyBuy
HC Wainwright & Co.2025-02-25
Maintains
BuyBuy
HC Wainwright & Co.2025-02-04
Maintains
BuyBuy
HC Wainwright & Co.2024-11-06
Maintains
BuyBuy
Oppenheimer2024-11-06
Maintains
OutperformOutperform
Oppenheimer2024-08-26
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on Entrada Therapeutics, Inc. (TRDA) stock. Of the recent 25 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover TRDA.

Analyst Recommendation Trends

Buy ratings202
Hold ratings01↑ +1
Sell ratings00

TRDA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$20M

↓ 64.7% YoY

Revenue Next Year

$29M

↑ 49.6% YoY

EPS This Year

$-3.96

EPS Next Year

$-3.58

↓ 9.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TRDA EPS of $-3.96 for the current fiscal year, based on estimates from 6 analysts. The TRDA revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TRDA stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TRDA price target is $16.00 (+155.6% upside), with an analyst consensus of Buy.

The TRDA short-term stock prediction for tomorrow is $6.23 (-0.42%). The TRDA stock price prediction for 2027 estimates an average of $8. The TRDA stock prediction for 2030 projects a range of $8–$12.

Entrada Therapeutics, Inc. trades on NASDAQ under the ticker TRDA. The TRDA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

TRDA forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month TRDA price target is $16.00, with a high forecast of $21.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +155.6% potential upside from the current price of $6.26.

TRDA price targetWhat is TRDA price targetTRDA analyst price targetTRDA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.